The era of genetic medicine has arrived. As scientists continue to unravel the mysteries of humanity’s genetic blueprint, their discoveries are driving the emergence of new types of therapies such as ...

The Carnegie Institution for Science and the University of Massachusetts Medical School (UMMS) have been granted United States Patent 8,283,329, entitled, "Genetic inhibition of double-stranded RNA." ...

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...

Researchers at the University of North Carolina at Chapel Hill have unveiled a platform technology designed to strengthen the potency of RNA interference therapies, a field that has promised targeted ...

Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...